Omeprazol Actavis (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Actavis, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease.

GNH USA supplies Omeprazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Actavis is a proton pump inhibitor that lowers gastric acidity in several gastrointestinal disorders.

- Gastroesophageal reflux disease (GERD): alleviates heartburn and acid regurgitation by decreasing stomach acid. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through acid suppression. - Helicobacter pylori eradication: used in combination therapy to enhance bacterial clearance. - Erosive esophagitis: heals inflamed esophageal tissue by maintaining a less acidic environment.

Adverse reactions may occur with omeprazole therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional feeling of stomach upset. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, consider the following safety measures.

- Assess renal and hepatic function: adjust use if impairment is present. - Review concomitant medications: avoid drugs that require gastric acidity for absorption. - Monitor for infection signs: prolonged acid suppression may increase gastrointestinal infection risk. - Evaluate long‑term use: consider bone health monitoring after extended therapy. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and light.

Omeprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular event risk. - Atazanavir: markedly decreased antiviral efficacy due to reduced absorption.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Methotrexate (high dose): possible increased toxicity, check serum levels. - Digoxin: may raise serum concentrations, observe for signs of toxicity.